Jeff Simmons1, Jean-Francois Pittet. 1. aAnesthesia Services Division, Trauma Section, UAB Department of Anesthesiology bCritical Care Division, Department of Anesthesiology cCenter for Lung Injury and Repair, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
PURPOSE OF REVIEW: Sepsis, defined by the presence of infection and host inflammation, is a lethal clinical syndrome with an increasing mortality rate worldwide. In severe disease, the coagulation system becomes diffusely activated, with consumption of multiple clotting factors resulting in disseminated intravascular coagulation (DIC). When present, DIC portends a higher mortality rate. Understanding the mechanisms that tie inflammation and diffuse thrombosis will allow therapeutic interventions to be developed. The coagulopathy of acute sepsis is a dynamic process that is time and disease burden specific. Whole-blood testing of coagulation may provide more clinically useful information than the classical tests. Natural anticoagulants that regulate thrombosis are downregulated in sepsis. Patients may benefit from the modulation of the coagulation system when systemic inflammation and hypercoagulopathy exist. Proper timing of anticoagulant therapy may ultimately lead to decreased incidence of multisystem organ dysfunction. RECENT FINDINGS: The pathogenesis of coagulopathy in sepsis is driven by an upregulation of procoagulant mechanisms and simultaneous downregulation of natural anticoagulants. Inflammation caused by the invading organism is a natural host defense that cannot be eliminated during treatment. Successful strategies to prevent multisystem organ dysfunction center on stratifying patients at high risk for DIC and restoring the balance of inflammation and coagulation. SUMMARY: The prevention of DIC in septic patients is a key therapeutic target in preventing death from multisystem organ failure. Stratifying patients for therapy using thromboelastometry, specific markers for DIC, and composite scoring systems is an area of growing research.
PURPOSE OF REVIEW: Sepsis, defined by the presence of infection and host inflammation, is a lethal clinical syndrome with an increasing mortality rate worldwide. In severe disease, the coagulation system becomes diffusely activated, with consumption of multiple clotting factors resulting in disseminated intravascular coagulation (DIC). When present, DIC portends a higher mortality rate. Understanding the mechanisms that tie inflammation and diffuse thrombosis will allow therapeutic interventions to be developed. The coagulopathy of acute sepsis is a dynamic process that is time and disease burden specific. Whole-blood testing of coagulation may provide more clinically useful information than the classical tests. Natural anticoagulants that regulate thrombosis are downregulated in sepsis. Patients may benefit from the modulation of the coagulation system when systemic inflammation and hypercoagulopathy exist. Proper timing of anticoagulant therapy may ultimately lead to decreased incidence of multisystem organ dysfunction. RECENT FINDINGS: The pathogenesis of coagulopathy in sepsis is driven by an upregulation of procoagulant mechanisms and simultaneous downregulation of natural anticoagulants. Inflammation caused by the invading organism is a natural host defense that cannot be eliminated during treatment. Successful strategies to prevent multisystem organ dysfunction center on stratifying patients at high risk for DIC and restoring the balance of inflammation and coagulation. SUMMARY: The prevention of DIC in septicpatients is a key therapeutic target in preventing death from multisystem organ failure. Stratifying patients for therapy using thromboelastometry, specific markers for DIC, and composite scoring systems is an area of growing research.
Authors: H Saito; I Maruyama; S Shimazaki; Y Yamamoto; N Aikawa; R Ohno; A Hirayama; T Matsuda; H Asakura; M Nakashima; N Aoki Journal: J Thromb Haemost Date: 2006-10-13 Impact factor: 5.824
Authors: Robert Silasi; Ravi Shankar Keshari; Cristina Lupu; Walter Janse Van Rensburg; Hala Chaaban; Girija Regmi; Aleksandr Shamanaev; Joseph J Shatzel; Cristina Puy; Christina U Lorentz; Erik I Tucker; David Gailani; András Gruber; Owen J T McCarty; Florea Lupu Journal: Blood Adv Date: 2019-02-26
Authors: Anis Chaari; Karim Abdel Hakim; Kamel Bousselmi; Mahmoud Etman; Mohamed El Bahr; Ahmed El Saka; Eman Hamza; Mohamed Ismail; Elsayed Mahmoud Khalil; Vipin Kauts; William Francis Casey Journal: World J Gastrointest Oncol Date: 2016-07-15
Authors: Steven L Raymond; David C Holden; Juan C Mira; Julie A Stortz; Tyler J Loftus; Alicia M Mohr; Lyle L Moldawer; Frederick A Moore; Shawn D Larson; Philip A Efron Journal: Biochim Biophys Acta Mol Basis Dis Date: 2017-01-20 Impact factor: 5.187
Authors: Paula M O'Shea; Graham Robert Lee; Tomás P Griffin; Vincent Tormey; Amjad Hayat; Seán J Costelloe; Damian Gerard Griffin; Saradha Srinivasan; Maurice O'Kane; Conor M Burke; John Faul; Christopher J Thompson; Gerard Curley; William P Tormey Journal: Ir J Med Sci Date: 2020-05-18 Impact factor: 1.568